Enzyme-linked immunosorbent assay (ELISA) is an analytic biochemical assay that utilizes enzyme-linked antibodies on a microwell platform to quantitate specific proteins within biological samples. Visual detection is then achieved by adding the enzyme’s substrate, which causes a color-changing reaction to occur. There are three different types of ELISA that are most commonly used: indirect ELISA, sandwich ELISA and competitive ELISA. These assays are extremely useful for high-throughput diagnostic screenings drug testing.
Novus offers a range of support options for ELISA when you buy a product to help you with your ELISA experiment including:
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Allophycocyanin | NB7446APC | |||
| Biotin | NB7446B | |||
| DyLight 350 | NB7446UV | |||
| DyLight 405 | NB7446V | |||
| DyLight 488 | NB7446G | |||
| DyLight 550 | NB7446R | |||
| DyLight 594 | NB7446DL594 | |||
| DyLight 650 | NB7446C | |||
| DyLight 680 | NB7446FR | |||
| DyLight 755 | NB7446IR | |||
| FITC | NB7448 | |||
| HRP | NB7449 | |||
| Janelia Fluor 525 | NB7446JF525 | |||
| Janelia Fluor 669 | NB7446JF669 | |||
| PE | NB7446PE | |||
| PerCP | NB7446PCP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-167SS | |||
| Azide and BSA Free | NBP2-80826 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | AF1118-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-442SS | |||
| Azide and BSA Free | NBP2-80727 | |||
![N/A IL-27 p28/IL-30 [HRP]](http://images.novusbio.com/fullsize2/DATA_IL27_p28_M2728_ELISA_930.jpg "N/A IL-27 p28/IL-30 [HRP]")
![N/A IL-27 p28/IL-30 [HRP]](http://images.novusbio.com/fullsize2/IL-27_p28_M2728_ELISA_233.jpg)
![N/A CXCL4/PF4 [HRP]](http://images.novusbio.com/fullsize2/DATA_CXCL4_DPF40_ELISA_787.jpg "N/A CXCL4/PF4 [HRP]")
![N/A CXCL4/PF4 [HRP]](http://images.novusbio.com/fullsize2/CXCL4_DPF40_ELISA_473.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-fragment-Secondary-Antibody-Immunohistochemistry-NB7446-img0002.jpg "Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.")
![Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Human-IgG-Fc-Secondary-Antibody-Western-Blot-NB7446-img0001.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416165644.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416154630.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416175295.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416163732.jpg)
![Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb7446_goat-polyclonal-goat-anti-human-igg-fc-secondary-antibody-310202416171447.jpg)
![Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)](http://images.novusbio.com/fullsize/LANA2-Antibody-CM-A807-Western-Blot-NB200-167-img0003.jpg "Western Blot: LANA2 Antibody (CM-A807) [NB200-167] - Detection of LANA2 in infected lysates (30 ug) using 2 ug/ml of NB 200-167. ECL detection 1.5 minutes. Lane 1: BCBL-1 (KSHV+) Lane 2: BC-1 (KSHV+/EBV+) Lane 3: BCP-1 (KSHV+)")
![Immunohistochemistry-Paraffin: LANA2 Antibody (CM-A807) [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource and performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA. Representative image shows the LANA staining of skin KS lesion. Image collected and cropped by CiteAb from the following publication (//mbio.asm.org/lookup/doi/10.1128/mBio.02217-17), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LANA2-Antibody-CM-A807-Immunohistochemistry-Paraffin-NB200-167-img0004.jpg)
![Immunohistochemistry: LANA2 Antibody (CM-A807) - BSA Free [NB200-167] - vIRF3 expression in KS tissues. We obtained KS tissue microarrays from AIDS Cancer Specimen Resource & performed immunohistochemistry, visualized by Aperio F.L. digital pathological scanning. A biopsy sample of KS TMA was stained with anti-LANA & anti-vIRF3 (CM-A807). Representative images show the LANA staining of skin KS lesion & the vIRF3 staining of skin, tonsil, & mouth KS lesions & positive staining corresponding to either LANA or vIRF3 in total KS biopsy specimens embedded in TMA. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29339432), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-167_mouse-monoclonal-lana2-antibody-cm-a807-310202415371954.jpg)
![N/A Dkk-1 [Biotin]](http://images.novusbio.com/fullsize2/DATA_Dkk1_DY1906_ELISA_1733.jpg "N/A Dkk-1 [Biotin]")
![N/A P-Selectin/CD62P [Biotin]](http://images.novusbio.com/fullsize2/DATA_PSelectin_DY137_ELISA_1636.jpg "N/A P-Selectin/CD62P [Biotin]")
![N/A Fetuin A/AHSG [HRP]](http://images.novusbio.com/fullsize2/DATA_Fetuin_A_DFTA00_ELISA_684.jpg "N/A Fetuin A/AHSG [HRP]")
![N/A Fetuin A/AHSG [HRP]](http://images.novusbio.com/fullsize2/DATA_Fetuin_A_DFTA00_ELISA_685.jpg)
![N/A Fetuin A/AHSG [HRP]](http://images.novusbio.com/fullsize2/Fetuin_A_DFTA00_ELISA_99.jpg)
![N/A IL-10 [HRP]](http://images.novusbio.com/fullsize2/DATA_IL10_P1000_ELISA_1053.jpg "N/A IL-10 [HRP]")
![N/A IL-10 [HRP]](http://images.novusbio.com/fullsize2/IL-10_P1000_ELISA_339.jpg)
![N/A IL-18 BPa/IL18BP [Biotin]](http://images.novusbio.com/fullsize2/DATA_IL18_BPa_DY119_ELISA_1598.jpg "N/A IL-18 BPa/IL18BP [Biotin]")
![Immunohistochemistry-Paraffin: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Mouse liver. Heme Oxygenase 1 stained by Heme Oxygenase 1 antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/HO-1-HMOX1-HSP32-Antibody-Immunohistochemistry-Paraffin-NBP1-31341-img0036.jpg "Immunohistochemistry-Paraffin: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Mouse liver. Heme Oxygenase 1 stained by Heme Oxygenase 1 antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.")
![Western Blot: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Analysis of HO-1 in HEK293 cell lysate using anti-HO-1 antibody. WB Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/HO-1-HMOX1-HSP32-Antibody-Western-Blot-NBP1-31341-img0017.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Nrf2-pathway activation by hybrids: nuclear translocation and targets induction. Protein levels by Western blot. Anti-actin was used as protein loading control. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32047434/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/HO-1-HMOX1-HSP32-Antibody-Western-Blot-NBP1-31341-img0032.jpg)
![Immunohistochemistry-Paraffin: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Human renal carcinoma . Heme Oxygenase 1 antibody diluted at 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min.](http://images.novusbio.com/fullsize/HO-1-HMOX1-HSP32-Antibody-Immunohistochemistry-Paraffin-NBP1-31341-img0019.jpg)
![Immunohistochemistry-Paraffin: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Rat spleen. Heme Oxygenase 1 stained by Heme Oxygenase 1 antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/HO-1-HMOX1-HSP32-Antibody-Immunohistochemistry-Paraffin-NBP1-31341-img0035.jpg)
![Western Blot: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Rat tissue extract (50 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with HO-1/HMOX1/HSP32 antibody (NBP1-31341) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31341_rabbit-polyclonal-ho-1-hmox1-hsp32-antibody-91020242001087.jpg)
![Immunohistochemistry-Paraffin: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - HO-1/HMOX1/HSP32 antibody detects HO-1/HMOX1/HSP32 protein at cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded mouse spleen.HO-1/HMOX1/HSP32 stained by HO-1/HMOX1/HSP32 antibody (NBP1-31341) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp1-31341_rabbit-polyclonal-ho-1-hmox1-hsp32-antibody-910202420104478.jpg)
![Western Blot: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Whole cell extract (30 ug) was separated by 12% SDS-PAGE, and the membrane was blotted with HO-1/HMOX1/HSP32 antibody (NBP1-31341) diluted at 1:1000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.](http://images.novusbio.com/fullsize/nbp1-31341_rabbit-polyclonal-ho-1-hmox1-hsp32-antibody-910202420104459.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HO-1/HMOX1/HSP32 Antibody [NBP1-31341] - Wild-type (WT) and Heme Oxygenase 1 knockout (KO) HeLa cell extracts (30 ug) were separated by 12% SDS-PAGE, and the membrane was blotted with Heme Oxygenase 1 antibody diluted at 1:500. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.](http://images.novusbio.com/fullsize/nbp1-31341_rabbit-polyclonal-ho-1-hmox1-hsp32-antibody-161020241941452.jpg)
![Flow Cytometry: Ethenoadenosine Antibody (1G4) [NB600-442] - Chicken erythrocytes (1% v/v), isolated by density gradient centrifugation, were transiently transfected with a Flag-tagged chicken ART4 containing plasmid or the empty plasmid (pSecTag B), and incubated at 37C in the presence or absence of 200 uM etheno-NAD+ for 30 min. After washing, cells were stained with an etheno-adenosine specific antibody (1G4) or an anti-Flag antibody and the respective isotype control stained with the 1G4 antibody. Image collected and cropped by CiteAb from the following publication (//bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-9-86), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ethenoadenosine-Antibody-1G4-Flow-Cytometry-NB600-442-img0002.jpg "Flow Cytometry: Ethenoadenosine Antibody (1G4) [NB600-442] - Chicken erythrocytes (1% v/v), isolated by density gradient centrifugation, were transiently transfected with a Flag-tagged chicken ART4 containing plasmid or the empty plasmid (pSecTag B), and incubated at 37C in the presence or absence of 200 uM etheno-NAD+ for 30 min. After washing, cells were stained with an etheno-adenosine specific antibody (1G4) or an anti-Flag antibody and the respective isotype control stained with the 1G4 antibody. Image collected and cropped by CiteAb from the following publication (//bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-9-86), licensed under a CC-BY license.")
![Flow Cytometry: Ethenoadenosine Antibody (1G4) [NB600-442] - Detection of ADP-ribosylated proteins by flow cytometry. C-33A cells (1 x 10^7/mL), transiently transfected with a Flag-tagged chicken ART4 containing plasmid, were incubated at 37C in the presence or absence of 200 uM etheno-NAD+ for 30 min. After washing, cells were stained with an etheno-adenosine specific antibody (1G4). Image collected and cropped by CiteAb from the following publication (//bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-9-86), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ethenoadenosine-Antibody-1G4-Flow-Cytometry-NB600-442-img0001.jpg)
![Flow Cytometry: Ethenoadenosine Antibody (1G4) [NB600-442] - Etheno-ADP-ribosylation of cell-surface proteins on C3H-10T1/2 cells. C3H-10T 1/2 cells at different stages of differentiation (progenitors, MyoD-myoblasts, myotubes) were incubated for 30 minutes in the absence (dashed lines) or presence (solid lines) of 100 uM etheno-NAD. Cells were then washed, incubated with the primary monoclonal antibody 1G4, stained with a FITC-conjugated goat-anti-mouse secondary antibody and subjected to FACS analysis. Data show one representative experiments out of three. Image collected and cropped by CiteAb from the following publication (//bmcmolbiol.biomedcentral.com/articles/10.1186/1471-2199-9-91), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ethenoadenosine-Antibody-1G4-Flow-Cytometry-NB600-442-img0003.jpg)